Children’s Hospital of Philadelphia

Stratasys opens enrollment is 3DHEART pediatric clinical study

Wednesday, March 8, 2017

Stratasys, a 3D printing and additive manufacturing solutions company, announced enrollment is now open for 3DHEART, an investigator initiated trial. 3DHEART, which stands for 3DHearts Enabling A Randomized Trial, is a randomized, single-blind clinical trial to study the use of patient-specific 3D printed models in pre-operative planning for pediatric heart surgery. Stratasys is providing in-kind support with printing of the models to be used in the trial.

[Read More]

GeoVax forms scientific advisory board

Tuesday, January 3, 2017

GeoVax Labs, a biotechnology company specializing in developing human vaccines, has announced the formation of its inaugural Scientific Advisory Board (SAB) to provide expert guidance as the company advances its vaccine development for multiple targets including HIV, hemorrhagic fever (Ebola, Sudan, Marburg, Lassa), Zika virus, chronic Hepatitis B and immuno-oncology.

[Read More]

The CenterWatch Weekly, October 03, 2016

Monday, October 3, 2016

CHOP launches pediatric genetic care initiative

A $50 million genetics care initiative was recently implemented by the Children’s Hospital of Philadelphia (CHOP) for the research of genetic diagnostics and clinical disease management in pediatric care. Termed the Roberts Collaborative for Genetics and Individualized Medicine, this initiative is largely funded by the Roberts family, the founders of Philadelphia-based Comcast, with a sizable donation contributing toward the integration of genetic research and education in all of CHOP’s clinical departments and centers.

[Read More]

CHOP launches Roberts Collaborative for Genetics and Individualized Medicine

Monday, September 26, 2016

The Children’s Hospital of Philadelphia (CHOP) has announced the creation of the Roberts Collaborative for Genetics and Individualized Medicine at CHOP. The $50 million Roberts Collaborative will position CHOP at the forefront of pediatric genetics research and will take a multidisciplinary approach toward diagnostics, clinical management, consulting, therapeutics and research driven by the power of genetics. The Roberts family is the principal source of external funding for this initiative, with a $25 million gift that will facilitate the integration of all clinical departments, divisions and centers for the care of pediatric patients, as well as advance a relentless pursuit of breakthrough cures for childhood disease.

[Read More]

CHOP, Seven Bridges form Cavatica for pediatric cancer genomics data

Friday, February 26, 2016

The Children’s Hospital of Philadelphia (CHOP), the lead operations center for the Childhood Brain Tumor Tissue Consortium (CBTTC), and Seven Bridges, a biomedical data analysis company, have announced the joint development of Cavatica, a new cloud-based environment for securely storing, sharing and analyzing large volumes of pediatric cancer patient genomics data. Cavatica will support CHOP’s commitment to the White House Precision Medicine Initiative (PMI) through the newly launched Center for Data Driven Discovery in Biomedicine (D3b), located at CHOP. 

[Read More]

NIH seeks ways to combine genomic information and EHRs

Wednesday, September 9, 2015

A dozen awards from the NIH will support research that incorporates DNA sequence information into electronic medical records. The goal of research conducted by the Electronic Medical Records and Genomics (eMERGE) network is to better understand the genomic basis of disease and to tailor medical care to individual patients based on their genomic differences.

[Read More]

Spark Therapeutics receives FDA Breakthrough Therapy designation for SPK-RPE65

Friday, November 7, 2014

Spark Therapeutics, a late-stage gene therapy company developing treatments for debilitating genetic diseases, has announced that its lead product candidate, SPK-RPE65, has received Breakthrough Therapy designation from the FDA. Breakthrough Therapy designation is intended to expedite the development and review of investigational therapies for serious or life-threatening conditions where initial clinical evidence demonstrates a significant improvement over existing therapies. SPK-RPE65 targets a group of blinding conditions known as inherited retinal dystrophies (IRDs) caused by autosomal recessive mutations in the RPE65 gene, and for which there currently is no pharmacologic treatment available.

[Read More]